Benitec Biopharma, Inc.
(NASDAQ : BNTC)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -4.48%178.260.0%$1736.06m
NVAXNovavax, Inc. -1.62%96.8578.2%$689.81m
AMGNAmgen, Inc. -0.64%232.331.4%$532.53m
BIIBBiogen, Inc. -0.45%232.761.8%$501.91m
GILDGilead Sciences, Inc. -1.04%69.701.0%$466.79m
BNTXBioNTech SE -1.11%167.360.0%$446.67m
REGNRegeneron Pharmaceuticals, Inc. 2.34%625.502.7%$405.44m
ILMNIllumina, Inc. 2.42%392.413.3%$394.96m
VRTXVertex Pharmaceuticals, Inc. 0.32%231.811.9%$335.28m
SNSSSunesis Pharmaceuticals, Inc. 0.33%3.010.7%$210.41m
EXASEXACT Sciences Corp. 1.40%78.5117.9%$156.33m
ARNAArena Pharmaceuticals, Inc. -0.39%91.6213.7%$144.85m
ALNYAlnylam Pharmaceuticals, Inc. 0.68%140.138.2%$140.06m
INCYIncyte Corp. 0.78%75.602.4%$133.96m
BMRNBioMarin Pharmaceutical, Inc. 0.75%87.364.2%$107.00m

Company Profile

Benitec Biopharma, Inc. is a development-stage biotechnology company, which focuses on the advancement of novel genetic medicines. The firms proprietary platforms includes DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy, and Chronic Hepatitis B. The company was founded on November 22, 2019 and is headquartered in Hayward, CA.